FibroBiologics, Inc.
FBLG
$0.26
-$0.02-5.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.90% | 5.14% | 8.89% | 10.48% | 38.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.23% | 50.30% | 39.27% | 31.33% | 49.68% |
| Operating Income | 30.23% | -50.30% | -39.27% | -31.33% | -49.68% |
| Income Before Tax | -4.68% | -1,055.60% | -618.71% | 41.30% | 68.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.68% | -1,055.60% | -618.71% | 41.30% | 68.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.68% | -1,055.60% | -618.71% | 41.30% | 68.11% |
| EBIT | 30.23% | -50.30% | -39.27% | -31.33% | -49.68% |
| EBITDA | 31.13% | -50.06% | -39.00% | -31.13% | -49.65% |
| EPS Basic | 40.64% | -800.00% | -540.15% | 50.17% | 73.62% |
| Normalized Basic EPS | 40.67% | -801.08% | -538.37% | 50.18% | 73.59% |
| EPS Diluted | 40.64% | -800.00% | -540.15% | 50.17% | 73.62% |
| Normalized Diluted EPS | 40.67% | -801.08% | -538.37% | 50.18% | 73.59% |
| Average Basic Shares Outstanding | 76.33% | 28.51% | 18.08% | 17.79% | 20.89% |
| Average Diluted Shares Outstanding | 76.33% | 28.51% | 18.08% | 17.79% | 20.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |